The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Therapeutics to reduce intracranial pressure are an unmet need. Preclinical data have demonstrated a novel strategy to lower intracranial pressure using glucagon-like peptide-1 (GLP-1) receptor signalling. Here, we translate these findings into patients by conducting a randomized, placebo-controlled, double-blind trial to assess the effect of exenatide, a GLP-1 receptor agonist, on intracranial pressure in idiopathic intracranial hypertension. Telemetric intracranial pressure catheters enabled long-term intracranial pressure monitoring. The trial enrolled adult women with active idiopathic intracranial hypertension (intracranial pressure >25 cmCSF and papilloedema) who receive subcutaneous exenatide or placebo. The three primary outcome measures were intracranial pressure at 2.5 h, 24 h and 12 weeks and alpha set a priori at less than 0.1. Among the 16 women recruited, 15 completed the study (mean age 28 ± 9, body mass index 38.1 ± 6.2 kg/m2, intracranial pressure 30.6 ± 5.1 cmCSF). Exenatide significantly and meaningfully lowered intracranial pressure at 2.5 h −5.7 ± 2.9 cmCSF (P = 0.048); 24 h −6.4 ± 2.9 cmCSF (P = 0.030); and 12 weeks −5.6 ± 3.0 cmCSF (P = 0.058). No serious safety signals were noted. These data provide confidence to proceed to a phase 3 trial in idiopathic intracranial hypertension and highlight the potential to utilize GLP-1 receptor agonist in other conditions characterized by raised intracranial pressure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The RAND-36 measure of health-related quality of life
Hays, R. D., & Morales, L. S. (2001) · Annals of Medicine · doi:10.3109/07853890109002089 · Cited by 1,460 · cited 1×
“Patient-reported outcome measures were assessed [Headache Impact Test-6 (HIT-6)(26) and 36-item short from survey (SF-36) Rand version].(27) Assessments were repeated at 12 weeks.”
MethodRubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444 · cited 1×
“This has led to GLP-1 receptor agonists being licensed to promote weight loss in the setting of obesity.(4)”
BackgroundA six-item short-form survey for measuring headache impact: The HIT-6™
Kosinski, M., Bayliss, M. S., Bjorner, J. B., Ware, J. E., Garber, W. H., Batenhorst, A., Cady, R., Dahlöf, C. G. H., Dowson, A., & Tepper, S. (2003) · Quality of Life Research · doi:10.1023/a:1026119331193 · Cited by 1,376
Glucagon-Like Peptide 1 Induces Natriuresis in Healthy Subjects and in Insulin-Resistant Obese Men
Gutzwiller, J.-P., Tschopp, S., Bock, A., Zehnder, C. E., Huber, A. R., Kreyenbuehl, M., Gutmann, H., Drewe, J., Henzen, C., Goeke, B., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031403 · Cited by 442
Stewart, P. M., Boulton, A., Kumar, S., Clark, P. M. S., & Shackleton, C. H. L. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.3.5538 · Cited by 398
Peng, H., Want, L. L., & Aroda, V. R. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0728-4 · Cited by 20
Cited by
Muayad, J., Loya, A., Hussain, Z. S., Chauhan, M. Z., Alsoudi, A. F., De Francesco, T., & Ahmed, I. I. K. (2025) · Ophthalmology · doi:10.1016/j.ophtha.2024.08.023 · Cited by 45
Stefanou, M., Chatziralli, I., Lambadiari, V., Mengel, A., Foska, A., Chondrogianni, M., Bakola, E., Tsalouchidou, P., Mitsikostas, D. D., Siasos, G., et al. (2025) · European Journal of Neurology · doi:10.1111/ene.70358 · Cited by 12
“Although gastrointestinal AEs are typically mild and self-limited in patients receiving GLP-1 RA treatment, they may represent a relevant limitation in RCT designs, likely introducing unmasking bias in patients undergoing active treatment [7].”
Influential
Metadata
- Authors
- Mitchell, J. L., Lyons, H. S., Walker, J. K., Yiangou, A., Grech, O., Alimajstorovic, Z., Greig, N. H., Li, Y., Tsermoulas, G., Brock, K., Mollan, S. P., & Sinclair, A. J.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-03-13
- Volume
- 146
- Issue
- 5
- Pages
- 1821-1830
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W4323981273
- Cited by
- 160
- References
- 6
- FWCI
- 23.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial. https://app.cochat.ai/papers/10.1093/brain/awad003
- The paper
- Mitchell, J. L., Lyons, H. S., Walker, J. K., Yiangou, A., Grech, O., Alimajstorovic, Z., Greig, N. H., Li, Y., Tsermoulas, G., Brock, K., Mollan, S. P., & Sinclair, A. J. (2023). The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial. Brain. https://doi.org/10.1093/brain/awad003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.